Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and ...
The Trump administration has rolled out a new website called TrumpRx, aimed at offering consumers lower prices on certain prescription drugs. The site, launched last week, lists discounted medications ...
Pfizer (PFE) announced on Friday that the U.S. Food and Drug Administration granted priority review for a marketing application seeking a label expansion for its hemophilia therapy, Hympavzi. The New ...
Pfizer has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its Hympavzi hemophilia drug for two patient populations with significant medical need ...
Exclusive interview with Pfizer CEO Albert Bourla as the company files for emergency use authorization for its COVID-19 vaccine from the FDA. Pfizer is the first ...
Pfizer signaled some promise in its long-running attempt to develop an anti-obesity drug on Tuesday, but analysts say limited results and missing safety information left Wall Street still uncertain ...
Pfizer shares fell 3.3% Tuesday on what some market watchers called underwhelming study results for an experimental weight-loss drug the drugmaker obtained after a contentious and costly bidding war ...
In Phase II data released this week, people taking a monthly dose of PF’3944 continued to lose more weight than those on a placebo. Reading time 2 minutes The competition to develop the next ...
Pfizer PFE2.07%increase; green up pointing triangle reported lower fourth-quarter sales as demand for its Covid-19 vaccine and antiviral drug continued to decline. The drugmaker reported a loss of ...
Pfizer said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. The data offer early evidence that the injection can ...
At the time of this analysis, the Braftovi combination regimen with FOLFIRI and cetuximab demonstrated a clinically meaningful and statistically significant improvement in confirmed objective response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results